EE+ POEM Archive
In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "In Patients With T2DM and Nephropathy, Canagliflozin Reduces Likelihood of End-stage Kidney Disease and Adverse CV Outcomes." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314815/all/In_patients_with_T2DM_and_nephropathy__canagliflozin_reduces_likelihood_of_end_stage_kidney_disease_and_adverse_CV_outcomes.
In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314815/all/In_patients_with_T2DM_and_nephropathy__canagliflozin_reduces_likelihood_of_end_stage_kidney_disease_and_adverse_CV_outcomes. Accessed April 24, 2024.
In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314815/all/In_patients_with_T2DM_and_nephropathy__canagliflozin_reduces_likelihood_of_end_stage_kidney_disease_and_adverse_CV_outcomes
In Patients With T2DM and Nephropathy, Canagliflozin Reduces Likelihood of End-stage Kidney Disease and Adverse CV Outcomes [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314815/all/In_patients_with_T2DM_and_nephropathy__canagliflozin_reduces_likelihood_of_end_stage_kidney_disease_and_adverse_CV_outcomes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes
ID - 1314815
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314815/all/In_patients_with_T2DM_and_nephropathy__canagliflozin_reduces_likelihood_of_end_stage_kidney_disease_and_adverse_CV_outcomes
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
